علاج الورم الدبقي قليل التغصنات من الدرجة 2 وفق تصنيف منظمة الصحة العالمية مع طفرة IDH وحذف 1p19q بعد الاستئصال الجراحي الكامل

References

DOI: 10.1200/JCO-25-00250

1. Within the group of people with oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO grade 2, initial radiation therapy and chemotherapy (with PCV or temozolomide) may be deferred until radiographic or symptomatic progression in some people with favorable prognostic factors (eg, complete resection and younger age) or concerns about toxicity.
2. People who are seeking pregnancy as either father or mother and people who are pregnant or breast feeding should not be offered vorasidenib.
3. People with oligodendroglioma, IDH-mutant, 1p19q co-deleted, CNS WHO grade 2 should be offered radiation in combination with procarbazine, lomustine, and vincristine (PCV) (Evidence quality: Moderate; Strength of recommendation: Strong).
4. Temozolomide is a reasonable alternative to PCV when toxicity is a concern (Evidence quality: Low; Strength of recommendation: Conditional).